» Articles » PMID: 15955404

The Social Structural Production of HIV Risk Among Injecting Drug Users

Overview
Journal Soc Sci Med
Date 2005 Jun 16
PMID 15955404
Citations 412
Authors
Affiliations
Soon will be listed here.
Abstract

There is increasing appreciation of the need to understand how social and structural factors shape HIV risk. Drawing on a review of recently published literature, we seek to describe the social structural production of HIV risk associated with injecting drug use. We adopt an inclusive definition of the HIV 'risk environment' as the space, whether social or physical, in which a variety of factors exogenous to the individual interact to increase vulnerability to HIV. We identify the following factors as critical in the social structural production of HIV risk associated with drug injecting: cross-border trade and transport links; population movement and mixing; urban or neighbourhood deprivation and disadvantage; specific injecting environments (including shooting galleries and prisons); the role of peer groups and social networks; the relevance of 'social capital' at the level of networks, communities and neighbourhoods; the role of macro-social change and political or economic transition; political, social and economic inequities in relation to ethnicity, gender and sexuality; the role of social stigma and discrimination in reproducing inequity and vulnerability; the role of policies, laws and policing; and the role of complex emergencies such as armed conflict and natural disasters. We argue that the HIV risk environment is a product of interplay in which social and structural factors intermingle but where political-economic factors may play a predominant role. We therefore emphasise that much of the most needed 'structural HIV prevention' is unavoidably political in that it calls for community actions and structural changes within a broad framework concerned to alleviate inequity in health, welfare and human rights.

Citing Articles

Gender and Intersecting Barriers and Facilitators to Access the HIV Cascade of Care in Manitoba, Canada, Before and During the COVID-19 Pandemic: A Qualitative Study.

Villacis-Alvarez E, Sobie C, Maier K, Lavallee M, Daniels C, Pashe H Trop Med Infect Dis. 2024; 9(12).

PMID: 39728814 PMC: 11679477. DOI: 10.3390/tropicalmed9120287.


Correction: Rapid Assessment Amid an Injection Drug Use-Driven HIV Outbreak in Massachusetts' Merrimack Valley: Highlights from a Case Study.

Rapisarda S, Silcox J, Case P, Palacios W, Stopka T, Zaragoza S AIDS Behav. 2024; 29(2):584-588.

PMID: 39676088 PMC: 11813815. DOI: 10.1007/s10461-024-04567-w.


HIV pre-exposure prophylaxis programmatic preferences among people who inject drugs: findings from a discrete choice experiment.

Eger W, Bazzi A, Valasek C, Vera C, Harvey-Vera A, Strathdee S Addict Sci Clin Pract. 2024; 19(1):81.

PMID: 39533335 PMC: 11555929. DOI: 10.1186/s13722-024-00505-2.


Rapid Assessment Amid an Injection Drug Use-Driven HIV Outbreak in Massachusetts' Merrimack Valley: Highlights from a Case Study.

Rapisarda S, Silcox J, Case P, Palacios W, Stopka T, Zaragoza S AIDS Behav. 2024; 29(2):562-583.

PMID: 39511061 PMC: 11813996. DOI: 10.1007/s10461-024-04540-7.


Safe Injection Self-Efficacy is Associated with HCV and HIV Seropositivity Among People Who Inject Drugs in the San Diego-Tijuana Border Region.

Bailey K, Abramovitz D, Rangel G, Harvey-Vera A, Vera C, Patterson T AIDS Behav. 2024; 28(11):3629-3642.

PMID: 39060837 PMC: 11537253. DOI: 10.1007/s10461-024-04433-9.